Evidence map›Paper›PMID 32586980›Full record

ArticleDiabetes2020

3-Hydroxyisobutyrate, A Strong Marker of Insulin Resistance in Type 2 Diabetes and Obesity That Modulates White and Brown Adipocyte Metabolism.

Mona S Nilsen, Regine Å Jersin, Arve Ulvik, André Madsen, Adrian McCann, Per-Arne Svensson, Maria K Svensson, Bjørn G Nedrebø, Oddrun A Gudbrandsen, Grethe S Tell and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Metabolomic profiles are reflective of hypoxia-induced insulin resistance during exercise in healthy young adult males.American journal of physiology. Regulatory, integrative and comparative physiology · 2021
    Trial
  4. The emerging role of branched-chain amino acid metabolism in obesity.International journal of obesity (2005) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Microbiome and Long COVID-19: Current Evidence and Insights.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Branched-chain amino acid metabolism: Pathophysiological mechanism and therapeutic intervention in metabolic diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Mona S NilsenMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Regine Å JersinMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Arve UlvikBevital AS, Bergen, Norway.
André MadsenHormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
Adrian McCannBevital AS, Bergen, Norway.ORCID 0000-0002-5728-5321
Per-Arne SvenssonDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Maria K SvenssonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Bjørn G NedrebøDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Oddrun A GudbrandsenDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Grethe S TellDepartment of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
C R KahnJoslin Diabetes Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-7583-9228
Per M UelandBevital AS, Bergen, Norway.
Gunnar MellgrenMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Simon N DankelMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway simon.dankel@uib.no.ORCID 0000-0001-6972-1824
Haukeland University Hospital · NOBevital (Norway) · NOUniversity of Bergen · NOJoslin Diabetes Center · USPrivatsykehuset Haugesund · NOUniversity of Gothenburg · SEUppsala University · SE

Funding

Developmental genes, miRNAs and adipose tissueR01DK082659 · NIDDK · JOSLIN DIABETES CENTER · PI C RONALD KAHN · 2009 to 2026
$10.7M
Interaction between genes, environment, the microbiome and metabolome in type 2 diabetes and metabolic syndromeR01DK121967 · NIDDK · JOSLIN DIABETES CENTER · PI KAHN, C RONALD · 2020 to 2024
$2.7M
NIDDK NIH HHS R01 DK082659NIDDK NIH HHS R01 DK121967
6 · The paper itself

Abstract

Circulating branched-chain amino acids (BCAAs) associate with insulin resistance and type 2 diabetes. 3-Hydroxyisobutyrate (3-HIB) is a catabolic intermediate of the BCAA valine. In this study, we show that in a cohort of 4,942 men and women, circulating 3-HIB is elevated according to levels of hyperglycemia and established type 2 diabetes. In complementary cohorts with measures of insulin resistance, we found positive correlates for circulating 3-HIB concentrations with HOMA2 of insulin resistance, as well as a transient increase in 3-HIB followed by a marked decrease after bariatric surgery and weight loss. During differentiation, both white and brown adipocytes upregulate BCAA utilization and release increasing amounts of 3-HIB. Knockdown of the 3-HIB-forming enzyme 3-hydroxyisobutyryl-CoA hydrolase decreases release of 3-HIB and lipid accumulation in both cell types. Conversely, addition of 3-HIB to white and brown adipocyte cultures increases fatty acid uptake and modulated insulin-stimulated glucose uptake in a time-dependent manner. Finally, 3-HIB treatment decreases mitochondrial oxygen consumption and generation of reactive oxygen species in white adipocytes, while increasing these measures in brown adipocytes. Our data establish 3-HIB as a novel adipocyte-derived regulator of adipocyte subtype-specific functions strongly linked to obesity, insulin resistance, and type 2 diabetes.

Indexed as

Adipocytes, BrownAdipocytes, WhiteAmino Acids, Branched-ChainBiomarkersBody CompositionCell DifferentiationDiabetes Mellitus, Type 2FemaleHumansHydroxybutyratesInsulin ResistanceMaleObesity3-hydroxyisobutyric acidAmino Acids, Branched-ChainBiomarkersHydroxybutyrates

Identifiers

PMID32586980
PMCPMC7968520
OpenAlexW3037981659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.